文献速递真菌感染

脑脊液早期杀菌活性作为隐球菌性脑膜炎临床试验生存替代终点

Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究汇总2010-2017年3项隐球菌性脑膜炎临床试验的738例个体数据,所有受试者接受两性霉素B联合氟康唑诱导治疗并连续做脑脊液定量培养。分析显示脑脊液隐球菌清除率(EFA)与18周全因死亡率相关,EFA<0.20 log10 CFU/mL/day者死亡率50%,而EFA≥0.20者为37%,风险比1.60。EFA阈值≥0.20 log10 CFU/mL/day或可作为替代终点目标。

要点

  • EFA<0.20 log10 CFU/mL/day与18周死亡率升高独立相关,风险比1.60。
  • EFA≥0.20者18周死亡率37%,低于EFA<0.20者的50%。
  • EFA阈值≥0.20 log10 CFU/mL/day可考虑作为替代终点目标。

核心结论

  • 脑脊液隐球菌早期杀菌活性(EFA)与隐球菌性脑膜炎全因死亡率相关。
  • EFA阈值≥0.20 log10 CFU/mL/day可作为替代终点的目标。

研究设计与样本

  • 汇总2010-2017年3项序贯隐球菌性脑膜炎临床试验的个体水平脑脊液数据,共738例。
  • 所有受试者接受两性霉素B联合氟康唑诱导治疗,并有连续脑脊液定量培养。
  • 对前10天每mL脑脊液log10转化菌落形成单位(CFU)与培养天数进行一般线性回归分析。

主要发现

  • 18周死亡率:EFA≥0.60为37%(n=170),0.40-0.59为36%(n=182),0.30-0.39为39%(n=112),0.20-0.29为35%(n=87),EFA<0.20为50%(n=187)。

关键数值与推荐

  • EFA≥0.20 log10 CFU/mL/day组18周死亡率为37%,EFA<0.20组为50%。

临床怎么用

  • 在隐球菌性脑膜炎临床试验中,可考虑将EFA≥0.20 log10 CFU/mL/day作为替代终点目标。
  • EFA可作为评估早期杀菌活性的指标,但需进一步验证其作为替代终点的适用性。

局限性

  • 研究为汇总3项临床试验的事后分析,非前瞻性验证。
  • EFA最低组CD4计数更低且脑脊液细胞增多比例更低,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint for all-cause mortality. The Food and Drug Administration allows for using surrogate endpoints for accelerated regulatory approval, but EFA as a surrogate endpoint requires further validation. We examined the relationship between rate of CSF Cryptococcus clearance (EFA) and mortality through 18 weeks. METHODS: We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during 2010-2017. All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitative CSF cultures. The log10-transformed colony-forming units (CFUs) per mL CSF were analyzed by general linear regression versus day of culture over the first 10 days. RESULTS: Mortality through 18 weeks was 37% for EFA > = 0.60 (n = 170), 36% for 0.40-0.59 (n = 182), 39% for 0.30-0.39 (n = 112), 35% for 0.20-0.29 (n = 87), and 50% for those with EFA < 0.20 CFU/mL/day (n = 187). The hazard ratio for 18-week mortality, comparing those with EFA < 0.20 to those with EFA > = 0.20, was 1.60 (95% confidence interval, 1.25, 2.04; P = .002). The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients with CSF pleocytosis (P < .001). CONCLUSIONS: EFA is associated with all-cause mortality in cryptococcal meningitis. An EFA threshold of > = 0.20 log10 CFU/mL/day was associated with similar 18-week mortality (37%) compared to 50% mortality with EFA < 0.20. This EFA threshold may be considered a target for a surrogate endpoint. This builds upon existing studies to validate EFA as a surrogate endpoint.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pullen MF, Hullsiek KH, Rhein J, et al. Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. Clin Infect Dis. 2020. PMID: 31912875. doi:10.1093/cid/ciaa016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。